Iowa
CNS medication trials in Iowa
12 CNS medication studies are recruiting participants at sites in 5 cities across Iowa as of November 17, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Iowa city with a recruiting study
By research area: Migraine (6), Depression (2), ADHD (1), Bipolar Disorder (1), Multiple Sclerosis (1), Parkinson's Disease (1).
Iowa City (4), West Des Moines (4), Ames (2), Sioux City (2), Waterloo (2).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Depression: recently updated in Iowa
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Neurocrine Biosciences
- Recruiting in
- Iowa City
- Registry record
- NCT07196501 · updated
Ketamine Alcohol (in Treatment-Resistant Depression)
- Phase 2
- Ages 18 to 55
- All sexes
- Sponsor
- Mark Niciu
- Recruiting in
- Iowa City
- Registry record
- NCT02122562 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Iowa on ClinicalTrials.gov.
Bipolar disorder: recently updated in Iowa
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Recruiting in
- Waterloo
- Registry record
- NCT07286175 · updated
Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Iowa on ClinicalTrials.gov.
ADHD: recently updated in Iowa
Stimulant Effects on Disruptive Behavior
- Phase 4
- From 48 months, up to 12 years
- All sexes
- Sponsor
- Matthew J O'Brien, PhD, BCBA-D
- Recruiting in
- Iowa City
- Registry record
- NCT03420339 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Iowa on ClinicalTrials.gov.
Parkinson's disease: recently updated in Iowa
Tenapanor in Synucleinopathy-Related Constipation
- Phase 2
- Ages 50 to 89
- All sexes
- Sponsor
- Cedar Valley Digestive Health Center
- Recruiting in
- Waterloo
- Registry record
- NCT06460038 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Iowa on ClinicalTrials.gov.
Multiple sclerosis (MS): recently updated in Iowa
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Recruiting in
- Iowa City
- Registry record
- NCT05877963 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Iowa on ClinicalTrials.gov.
Migraine: recently updated in Iowa
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Recruiting in
- Ames · Sioux City
- Registry record
- NCT07816367 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Recruiting in
- West Des Moines
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Recruiting in
- West Des Moines
- Registry record
- NCT07674654 · updated
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Recruiting in
- Sioux City · West Des Moines
- Registry record
- NCT04649242 · updated
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Recruiting in
- West Des Moines
- Registry record
- NCT04743141 · updated
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- AbbVie
- Recruiting in
- Ames
- Registry record
- NCT05125302 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Iowa on ClinicalTrials.gov.
Ask about studies in Iowa
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.
CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections